FDA Keeps Avandia On The Market But Looks To RECORD For More Clarity On CV Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.
You may also be interested in...
CEO Witty's 2017 Exit Could Hasten Glaxo's Consumer Business Decision
Glaxo CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change. His biggest legacy could be the multi-asset swap he orchestrated with Novartis in 2014 that created a consumer health care JV with the Swiss firm.
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.